heat shock protein 90 alpha family class A member 2, pseudogeneGenealiases: HSP90AA2 · HSP90ALPHA · HSPCA · HSPCAL3
Q-omics provides the consensus-scored HSP90AA2P profile across patient tissues and cancer cell-line models. HSP90AA2P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HSP90AA2P is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, HSP90AA2P RNA expression shows 18,160 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where HSP90AA2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSP90AA2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSP90AA2P survival associations across molecular data types. HSP90AA2P RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSP90AA2P RNA expression–survival associations across cancer types. High HSP90AA2P expression shows unfavorable associations in UVM, BRCA, ESCA and MESO, but favorable associations in KIRC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HSP90AA2P RNA expression.
This table summarizes HSP90AA2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSP90AA2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSP90AA2P shows lower tumor expression in KIRC and higher tumor expression in COAD, HNSC, STAD, LIHC and BLCA. The COAD box plot shows higher HSP90AA2P RNA expression in tumor versus normal tissue (log2 FC = +1.313, t-test p < 0.001).
This table shows molecular features associated with HSP90AA2P in patient tissues and cancer cell lines. In patient samples, HSP90AA2P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSP90AA2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
